Avalon Globocare Corp Stock

$0.28-0.01 (-3.45%)
Updated May 17, 2024
ALBT Price
Fair Value Price
Market Cap
52 Week Low
52 Week High
Dividend Yield
Gross Margin
Operating Margin
Profit Margin
Debt to Equity
Operating Cash Flow
Next Earnings
May 20, 2024
Next Dividend

ALBT Overview

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ALBT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ALBT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ALBT is good value based on its book value relative to its share price (0.42x), compared to the US Real Estate Services industry average (2.7x)
P/B vs Industry Valuation
ALBT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ALBT due diligence checks available for Premium users.

Be the first to know about important ALBT news, forecast changes, insider trades & much more!


ALBT fair value

Fair Value of ALBT stock based on Discounted Cash Flow (DCF)
Fair Value
Overvalued by
ALBT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ALBT price to earnings (PE)

For valuing profitable companies with steady earnings

ALBT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
ALBT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ALBT's financial health

Profit margin

Net Income
Profit Margin
ALBT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ALBT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Debt to equity
ALBT's short-term liabilities ($6.76M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALBT's long-term liabilities ($6.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALBT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ALBT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

ALBT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ALBT vs Real Estate Service Stocks

TickerMarket Cap1d %P/EP/B

Avalon Globocare Stock FAQ

What is Avalon Globocare's quote symbol?

(NASDAQ: ALBT) Avalon Globocare trades on the NASDAQ under the ticker symbol ALBT. Avalon Globocare stock quotes can also be displayed as NASDAQ: ALBT.

If you're new to stock investing, here's how to buy Avalon Globocare stock.

What is the 52 week high and low for Avalon Globocare (NASDAQ: ALBT)?

(NASDAQ: ALBT) Avalon Globocare's 52-week high was $2.42, and its 52-week low was $0.24. It is currently -88.47% from its 52-week high and 16.25% from its 52-week low.

How much is Avalon Globocare stock worth today?

(NASDAQ: ALBT) Avalon Globocare currently has 11,104,534 outstanding shares. With Avalon Globocare stock trading at $0.28 per share, the total value of Avalon Globocare stock (market capitalization) is $3.10M.

Avalon Globocare stock was originally listed at a price of $27.50 in Nov 6, 2018. If you had invested in Avalon Globocare stock at $27.50, your return over the last 5 years would have been -98.99%, for an annualized return of -60.07% (not including any dividends or dividend reinvestments).

How much is Avalon Globocare's stock price per share?

(NASDAQ: ALBT) Avalon Globocare stock price per share is $0.28 today (as of May 17, 2024).

What is Avalon Globocare's Market Cap?

(NASDAQ: ALBT) Avalon Globocare's market cap is $3.10M, as of May 19, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Avalon Globocare's market cap is calculated by multiplying ALBT's current stock price of $0.28 by ALBT's total outstanding shares of 11,104,534.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.